Akums Drugs Gets EU GMP Approval For Two Manufacturing Plants

Akums Drugs & Pharmaceuticals Ltd., the contract manufacturing pharmaceutical company in India, has recently acquired the European Union (EU) Good Manufacturing Practice (GMP) approval for two of their manufacturing units in Haridwar. Following this nod, the gateway for several new opportunities in the European and other regulatory markets is about to open to Akums Drugs.  

Of the two approved plants, one plant manufactures solid oral dosage forms such as tablets, hard gelatin capsules, powders in sachets, etc. belonging to the general category, and the other manufactures the large-volume and small-volume parenterals range including vials, ampoules, eyedrops, FFS as well as dry powder injections belonging to the penicillin line.    

“We are happy to announce that Akums Drugs has received the EU GMP approval for two of our Haridwar-based manufacturing facilities, thus paving the path for new opportunities from the entire EU as well as many other regulatory markets. We are manufacturing over 12 per cent of the country’s domestic supply. What makes us happiest, however, is being recognised for our “Quality First” approach. While we have been endorsed for this quality by our partners who are also leading Indian and multinational pharmaceutical companies, the latest nod from the EU GMP is a widely recognised and accepted one. Congratulations to the entire team, and hope this is the beginning of numerous possibilities for us” said Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, Shri Sandeep Jain. 

The pharma company is set to get access to markets in the European Union as well as many other markets like South Africa, Canada, Malaysia, Indonesia, Thailand, Australia/New Zealand and most middle-eastern countries based on the approval from EU GMP.